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Abstract 
IDH wild type (IDHwt) anaplastic astrocytomas WHO grade III (AA III) are associated with poor 
outcome. To address the possibilities of molecular subsets among astrocytoma or of diagnostic 
reclassification, we analyzed a series of 160 adult IDHwt tumors comprising 120 AA III and 40 diffuse 
astrocytomas WHO grade II (A II) for molecular hallmark alterations and established methylation and 
copy number profiles. Based on molecular profiles and hallmark alterations the tumors could be 
grouped into four major sets. 124/160 (78%) tumors were diagnosed as the molecular equivalent of 
conventional glioblastoma (GBM), and 15/160 (9%) as GBM-H3F3A mutated (GBM-H3). 13/160 (8%) 
exhibited a distinct methylation profile that was most similar to GBM-H3-K27, however, lacked the 
H3F3A mutation. This group was enriched for tumors of infratentorial and midline localization and 
showed a trend towards a more favorable prognosis. All but one of the 120 IDHwt AA III could be 
assigned to these three groups. 7 tumors recruited from the 40 A II, comprised a variety of molecular 
signatures and all but one were reclassified into distinct WHO entities of lower grades. Interestingly, 
TERT mutations were exclusively restricted to the molecular GBM (78%) and associated with poor 
clinical outcome. However, the GBM-H3 group lacking TERT mutations appeared to fare even worse. 
Our data demonstrate that most of the tumors diagnosed as IDHwt astrocytomas can be allocated to 
other tumor entities on a molecular basis. The diagnosis of IDHwt diffuse astrocytoma or anaplastic 
astrocytoma should be used with caution.  
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Introduction 
 
Classification of diffuse astrocytic tumors 
The classification of astrocytomas according to WHO 2007 predominantly relies on the evaluation of 
histopathology and immunohistochemistry [12]. In the recent years molecular parameters have been 
developed and proven powerful astrocytoma classifiers. In fact, the previously well accepted and quite 
harmonious WHO classification scheme for astrocytomas has experienced challenges by molecular 
findings that are not reflected in morphology. The presence of isocitrate dehydrogenase 1 (IDH1) and 
isocitrate dehydrogenase 2 (IDH2) mutations in the majority of diffuse astrocytomas WHO grade II (A 
II) and anaplastic astrocytomas WHO grade III (AA III) and their association with a more favorable 
course, especially in AA III are strong evidence that heterogeneous tumors have been lumped 
together under a single diagnosis. There is increasing evidence from multiple studies, that the poor 
clinical outcome of IDHwt AA III is a result of a considerable proportion of unrecognized glioblastoma 
(GBM) in this group [2,4,22,26]. Such evidence is based on an overlap of distinct molecular lesions in 
IDHwt AA III and GBM and on similar clinical courses. It remains to be tested, how many IDHwt A II or 
IDHwt AA III cannot be allotted to other tumor entities by molecular analyses. 
 
Frequency of IDH1 and IDH2 mutations in WHO 2007 classified and graded astrocytomas 
Upon recognition of IDH mutations in a series of GBM, predominantly secondary GBM [16], several 
studies demonstrated IDH1 or IDH2 mutations in A II or AA III. The percentages of IDH mutations 
given for A II ranged from 59% to 90% and those for AA III from 52% to 78% [1,5-7,25,28]. 
Interestingly, the frequency of IDH mutations in all studies was higher in A II than in AA III. 
 
Aim and design of the study 
The present study was designed to interrogate the hypothesis that the group of IDHwt astrocytoma is 
in fact composed of distinctive pathobiological entities. A series of 160 adult IDHwt A II or IDHwt AA III 
was analyzed for molecular parameters consistent with other brain tumor entities. The overall survival 
(OS) of these subgroups was compared to that of the brain tumor entity in question. 
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Material and Methods 
 
Tissue collection 
For the Heidelberg series, paraffin blocks containing tissue of adult patients (18 years of age and 
older) with IDHwt A II or AA III were collected from the archives of the Neuropathology departments of 
the Universities Heidelberg, Münster and Zurich, the UCL Institute of Neurology (08/H0716/16) and 
from the German Glioma Network (GGN). Tumors with 1p/19q co-deletion were excluded. One 
reference set was extracted from a recently published series by the TCGA (n=231) [2]. Therefore, the 
results here are in part based upon data generated by the TCGA Research Network: 
http://cancergenome.nih.gov/.  
 
Determination of copy number alterations and G-CIMP phenotype by 450k array analysis 
The Illumina Infinium HumanMethylation450 BeadChip (450k) array was used to determine the DNA 
methylation status of 482,421 CpG sites (Illumina, San Diego, USA) according to the manufacturer’s 
instructions at the Genomics and Proteomics Core Facility of the DKFZ. The array data was used to 
calculate a low-resolution copy number profile (CNP) as previously described [21]. Further, the data 
were analyzed as previously described to allot the tumors to either a G-CIMP or a non-G-CIMP cluster 
[27]. 
 
IDH1/IDH2, H3F3A and TERT promoter mutation analyses 
Primer design for sequencing was based on accession numbers NM_005896 for IDH1, NM_002168 
for IDH2 and NM_002107.4 for H3F3A (http://www.ncbi.nlm.nih.gov). Primers for IDH1: forward 5’- 
TGATGAGAAGAGGGTTGAGGA-3’; reverse 5’-GCAAAATCACATTATTGCCAAC-3’ and for IDH2: 
forward 5’-CTCCACCCTGGCCTACCT-3’; reverse 5’-GCTGCAGTGGGACCACTATT-3’.PCR and 
sequencing was performed as previously described [5]. Primers for H3F3A: forward 5’-
CATGGCTCGTACAAAGCAGA-3’; reverse 5’-CAAGAGAGACTTTGTCCCATTTTT-3’. PCR and 
sequencing was performed as previously described [20]. A 163 bp fragment of the TERT promoter 
region spanning the hotspot mutations at positions 1,295,228 and 1,295,250 was amplified by using 
GoTaq G2 Hot Start Polymerase (Promega, Madison, USA) and the primers hTERT-short-for 5´-
CAGCGCTGCCTGAAACTC-3´ and hTERT-short-rev, 5’-GTCCTGCCCCTTCACCTT-3’ as previously 
described [9]. Sequences were determined using a semi-automated sequencer (ABI 3100 Genetic 
Analyzer, Applied Biosystems, Foster City) and Sequence Pilot version 3.1 software (JSI-Medisys, 
Kippenheim, Germany). 
 
Immunohistochemistry  
Immunohistochemistry was conducted on 4 µm thick formalin-fixed, paraffin-embedded (FFPE) tissue 
sections mounted on StarFrost Advanced Adhesive slides (Engelbrecht, Kassel, Germany) followed 
by drying at 80°C for 15 min. Immunohistochemistry was performed on a BenchMark Ultra 
immunostainer (Ventana Medical Systems, Tucson, AZ, USA). Sections were stained with anti-IDH1-
R132H antibody H09 (Dianova, Hamburg, Germany) as previously described [3]. ATRX 
immunohistochemistry was performed as previously described [19]. In brief, after deparaffinization, 
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slides were pretreated at 95°C in Cell Conditioning 1 buffer (Ventana) for 90 minutes. The sections 
were incubated with primary antibody HPA001906 (Sigma-Aldrich, St. Louis, MO; USA) diluted 1:200 
for 2 hours. Standard Ventana signal amplification was used. For BRAFV600E staining V600E-specific 
clone VE1 was used. After pretreatment with cell conditioner 1 (pH 8) for 64 min, sections were 
incubated with VE1 hybridoma supernatant (monoclonal, dilution 1:5) at 37°C for 32 min. Antibody 
incubation was followed by OptiView HQ Universal Linker for 12 min, incubation with OptiView HRP 
Multimer for 12 min, signal amplification including the Ventana OptiView Amplification Kit (Ventana, 
catalogue number 760-099). 
 
Statistics 
The Kaplan–Meier plots and log-rank were conducted by JMP statistics software (version 9.0.0; SAS 
Institute, Cary, NC, USA). The 450k data was processed with the Bioconductor package minfi (version 
1.12). For the unsupervised hierarchical clustering only CpGs with a standard deviation (sd) greater 
0.2 across the beta values were selected. The samples were clustered with Ward's linkage method 
and the pairwise similarity was calculated using the Euclidean distance. For the hierarchical clustering 
of the CpGs average linkage and the Euclidian distance were applied. R version 3.1.3 and 
Bioconductor version 3.0 were used. 
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Results and Discussion 
 
Study and reference groups 
In order to compare tumors diagnosed as IDHwt astrocytoma with other entities, a study and a 
reference set were formed. The study set contained 160 IDHwt astrocytomas with 40 being diagnosed 
as diffuse A II and 120 as AA III. The reference set contained 132 IDH mutated (IDHmut) 
astrocytomas, 100 IDHwt GBM and 21 H3F3A mutated gliomas (GBM-H3-K27 and GBM-H3-G34). All 
tumors of both study and reference groups were subjected to 450k methylation analysis, and low 
resolution copy number profiles were calculated from the methylation data. For comparison of OS a 
TCGA control cohort of 105 IDHmut anaplastic astrocytomas was used. 
Molecular hallmark lesions in IDHmut and IDHwt astrocytic tumors of the reference cohort 
associate with distinct methylation patterns  
Unsupervised hierarchical clustering of the tumors in the reference set revealed two main 
methylation clusters perfectly matching the IDH status (suppl. fig.1). Given the dominant 
hypermethylation phenotype of IDHmut tumors [14,23] we then re-clustered the IDHwt tumors 
separately in order to achieve a more refined differentiation (suppl. fig.2).  
The IDHwt tumors segregated into two main clusters. One of these clusters was composed 
only of GBM cases which again formed two subclusters reminiscent of the “mesenchymal” and 
“classic” methylation groups [21]. The second main cluster was enriched for H3F3A-mutant cases. 
The G34 and K27 mutant cases formed homogenous subclusters within this cluster confirming the 
reported distinctiveness of methylation profiles associated with both mutations [21]. A third subcluster 
composed of GBM cases reminiscent of the previously reported “RTK1” methylation cluster was also 
present [21]. Of note, two of the GBM reference cases formed a small subcluster adjacent to the 
H3F3A-K27 mutant cluster. Both cases were sequenced and found to be wild type for H3F3A.  
In line with previous reports, [8] TERT promoter mutations were found in 88% of all GBM 
cases irrespective of the methylation cluster but in only 2/132 (1%) IDHmut cases and in none of the 
H3F3A mutant cases. TERT mutation is therefore considered a hallmark lesion for GBM. Analysis of 
CNPs confirmed 7p gain/10q loss to be highly characteristic for GBMs. In 88% of such cases the 
whole chromosomes were affected. 7p gain/10q loss was present in 75% of cases in the GBM cluster 
and in 20% of GBM-H3-G34 but absent in all IDHmut and GBM-H3-K27 cases. EGFR amplification 
was detected in 38 % of GBMs but in only 1/132 IDHmut cases. EGFR amplification was differently 
distributed between the various GBM methylation groups with the highest frequency in the “classic” 
cluster. The combination of loss of the entire arm 10q combined with partial or complete losses on 13q 
and 14q was recognized as a distinct pattern present in 20% of GBM but absent in other groups. 
Therefore, 7p gain/10q loss, EGFR amplification and the combination of loss of the entire arm 10q 
combined with losses on 13q and 14q were also considered hallmark lesions for GBM. At least one of 
these hallmark alterations was present in 96% of GBM cases. The distribution of molecular lesions in 
the reference sets is given in suppl. table 1. Typical examples for CNPs are provided in fig.1. 
H3F3A mutated gliomas exhibit morphological features of both, GBM and AA III. Clinically the 
presence or absence of necrosis has not been shown to be of prognostic relevance, and the clinical 
course of these patients is similar to those with GBM. For these reasons we pooled these tumors 
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under the provisional designation GBM H3F3A mutated (GBM-H3). GBM-H3 frequently showed loss 
of chromosomal material or complex alterations on 3q (48%) and frequently was accompanied by gain 
of 17q (33%). In GBM-H3-K27 there was frequently a gain (45%) or occasionally an amplification of 
MDM2 (9%), often with a co-gain of CDK4 (45%), a feature shared with a minority of GBMs (9%) but 
virtually absent in all other cases. Interestingly, the two H3F3A wild type GBM reference cases 
clustering adjacent to H3F3A-K27 mutant GBM lacked conventional GBM hallmark alterations and 
exhibited CNP reminiscent to H3F3A mutant GBMs. 
ATRX loss was present in 96% of IDHmut astrocytomas, in 5/5 GBM-H3-G34, in 5/6 GBM-H3-
K27, but only in 3/94 (3%) GBM. A compilation of the alterations in the respective reference sets is 
provided in supplementary tbl.1.  
 
Establishing “integrated” diagnoses for IDH wild type astrocytomas and comparison with 
clinical outcomes 
For the analysis of the study set, composed exclusively of IDHwt astrocytomas we used the 
same clustering strategy as for the reference set. First the IDHwt astrocytomas were clustered with the 
reference set to identify possible cases with a G-CIMP phenotype. Two tumors (1%) exhibited a G-
CIMP phenotype and mapped to the IDHmut cluster despite showing IDH1/2 wild type sequences in 
Sanger sequencing and were provisionally designated astrocytoma-IDH-like. The remaining cases 
were then re-clustered without the IDHmut reference set. Based on the distribution of the molecular 
findings, the IDHwt astrocytoma set could be subdivided in four major groups (fig.2a). OS of the four 
groups is given in fig.3a. 
All tumors were assessed for distinct molecular lesions. The integrated diagnosis of GBM was 
assigned to 124/160 (78%) tumors. 115 tumors segregated to a GBM cluster and showed at least one 
of the GBM hallmark alterations TERT promoter mutation, 7p gain/10q loss, EGFR amplification or 
combined 10q/13q/14q deletion. Additional 6 tumors segregated to the GBM cluster and showed 
complex CNPs with gains and losses involving several chromosomes or gene amplifications. 
Therefore these tumors were also considered to be GBMs. Two additional cases that clustered 
adjacent to GBM-H3-K27 cases but showed TERT promoter mutations were classified as GBMs. A 
single case which clustered together with GBM-H3-G34 case but was H3F3A wild type and showed a 
complex CNP with EGFR amplification was also classified as GBM. 
Accounting for 78% of cases this was by far the most numerous group. Median survival in this 
group was 19.4 months - very well matching survival seen in GBM patients and thus further justifying 
the diagnosis of GBM. Presence or absence of TERT promoter mutations did not affect survival in this 
group. 
15 (9%) tumors exhibited a methylation profile typical of H3F3A mutated GBM and indeed 
harbored hotspot mutations; 12 were GBM-H3-K27 and three GBM-H3-G34. This group of 15 patients 
predominantly containing H3F3A-K27 mutations exhibited a median survival of 16.9 months matching 
the observation of very poor clinical courses in pediatric glioma with H3F3A-K27 mutations [21,24]. 
Comparison of OS of this group with that of a control cohort of IDHmut astrocytoma is shown in fig.3b. 
H3F3A mutations were highly associated with loss of nuclear expression of ATRX (8/11 cases, 73%) 
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which further emphasizes that this group represents a clearly defined GBM. Likewise, the lack of 
TERT mutations further separates GBM-H3 from classical GBM. 
Thirteen tumors (8%) with a distinct methylation profile clustering adjacent to GBM-H3-K27 
lacked H3F3A mutations. These tumors did not exhibit the hallmark alterations of GBM but showed 
complex CNP with overlaps to both G34 and K27 H3F3A mutant GBMs. This group was enriched for 
tumors of midline localization and has not previously been described. The median survival of 54.7 
months may indicate a more favorable course than that of GBM patients, and, therefore this group 
may qualify as a second astrocytoma subgroup apart from IDHmut astrocytoma (fig.3c). Since OS still 
is shorter than that of IDHmut astrocytoma, we suggest that grouping with malignant astrocytic tumors 
may be appropriate (fig.3c). Therefore, this tumor group was provisionally termed ‘midline high grade 
glioma’ (MID-HGG).  
6/160 (5%) cases assigned to a common subcluster within the large GBM cluster lacked all 
hallmark alterations and demonstrated a CNP that was either completely balanced or showed only 
minor chromosomal alterations or trisomies. These cases were considered to most likely comprise an 
assortment of other lower-grade neuroepithelial tumors. Case 3276 exhibited a CNP with several 
whole chromosomal gains including chromosomes 5 and 7. This pattern is typical for low grade 
glioneuronal tumors and is absent in diffuse astrocytomas [17]. Furthermore this case harbored a 
BRAFV600E mutation strongly suggestive of ganglioglioma [10]. Case 68924 showed a similar CNP 
with trisomies of chromosomes 5, 7 and 20. Histologic re-evaluation demonstrated an Alcian-blue 
positive tumor matrix and an astrocytic as well as an oligodendroglial appearance of the tumor cells. 
Even though “floating neurons” were not found in this small biopsy a dysembryoplastic neuroepithelial 
tumor (DNT) seems the most likely diagnosis. A similar histological constellation was present in case 
72220 which exhibited a completely balanced CNP. Similarly, case 72274 did not show any 
chromosomal aberrations and histological re-evaluation revealed an atypical ganglion cell component 
in this tumor consistent with ganglioglioma. Histological re-evaluation of case 49164 revealed tumor 
areas with bipolar tumor cells and Rosenthal-fibers suggestive of pilocytic astrocytoma. Case 50133 
had a unique methylation profile and a copy number profile showing gain of chromosome 12 and 
losses of chromosomes 13 and 22q. Histological re-evaluation revealed an overall low but 
perivascular accentuated GFAP expression and a “dot-like” EMA expression. It was concluded that 
this spinal tumor should be re-diagnosed as ependymoma.  
Thus, molecular analyses completely resolved this group of morphologically diagnosed IDHwt 
astrocytomas into established entities. A compilation on the molecular alterations of IDHwt 
astrocytomas is provided in tbl.1. The data for each individual tumor are listed in suppl. tbl.2. The 
changes from the initial WHO diagnosis to an integrated diagnosis are shown in fig.4.  
In conclusion these data demonstrate that 139/160 (87%) of IDHwt astrocytomas on molecular 
and clinical grounds are indistinguishable from GBM or GBM-H3. Interestingly, upon separation of 
GBM from GBM-H3, the latter having the least favorable prognosis, the presence of TERT mutations 
in the GBM group did not influence survival (suppl. Fig. 3). 6/160 tumors were misdiagnosed other 
lower grade gliomas. Most interestingly, a group of 13 tumors emerged with a distinct methylation 
profile most similar to GBM-H3-K27 and enriched for midline tumors but lacked a H3F3A mutation. 
This group showed a trend towards better survival than GBMs. 
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Implication for future diagnostic approach to diffuse and anaplastic astrocytomas 
In-depth genome wide molecular genetic analysis is available only to few diagnostic 
institutions. Even more common analysis methods, such as fluorescent in situ hybridization or gene 
sequencing are not affordable to all departments and access to immunohistochemistry can be limited 
in countries with emerging markets. That said, even with the absence of immunohistochemical and 
molecular genetic analyses tumors must be classifiable to provide a basis for therapy. In a recent 
meeting under sponsorship of the International Society of Neuropathology (ISN) held in Haarlem, the 
Netherlands, the consensus “ISN-Haarlem” guidelines were developed [13]. One notable proposition 
was the introduction of a “not otherwise specified” (NOS) category for tumors which could not be 
analyzed by IHC and/or molecular genetics in a desired way. While this is an important and pragmatic 
approach, it must be made very clear that the diagnoses of astrocytoma NOS, of astrocytoma IDHmut 
and of astrocytoma IDHwt refer to patients with very different characteristics: The diagnosis 
astrocytoma NOS inevitably will contain IDHmut astrocytomas and a considerable proportion of GBM, 
and less frequently other tumor entities as well as some oligodendrogliomas. The IDHmut astrocytoma 
group can be expected to be quite homogenous, however will contain some oligodendrogliomas which 
do require 1p/19 analysis for exclusion. Most problematic is the group of IDHwt astrocytomas 
because, as we show in this study, this set contains a variety of entities with defined molecular 
patterns. In the present series, 83% of IDHwt astrocytomas exhibited clear molecular and clinical traits 
of GBM or GBM-H3. Related to this group are astrocytomas negatively scoring with the IDH1-R132H 
specific antibody. Because no more than 10% of all IDH mutations in diffuse glioma are other than the 
IDH1-R132H type, this group can be expected to consist predominantly of GBM or GBM-H3. A 
schematic summary of this concept problem is given in fig.5. 
Astrocytoma NOS is reserved for cases in which molecular characterization is not available. 
Most cases in which the IDH-R132H mutation has been excluded by immunohistochemistry, but which 
have not been sequenced for rare mutations, will be IDHwt and thus are best separated from the NOS 
designation. 
The diagnosis of IDHmut astrocytoma can be considered to define a molecular and clinical 
homogenous entity. In fact, recent evidence points to only minor differences in clinical characteristics 
between patients with IDHmut diffuse A II and A III [2,15,18,22]. We strongly recommend to use every 
possibility to come to this diagnosis by IHC with IDH1-R132H specific antibodies and, if required by 
sequencing exons 4 of IDH1 and IDH2.  
In the face of the steadily increasing number of molecular parameters of potential diagnostic 
relevance, neuropathological practice must aim at reducing additional assays to the necessary. In our 
experience, a feasible approach further refined from a previous report [19] towards the diagnosis of 
diffuse gliomas starts with the analysis of ATRX and IDH1-R132H (H09) immunohistochemistry. A 
large group consisting of astrocytomas exhibiting nuclear ATRX loss and positively staining with IDH1-
R132H antibody does not require further analysis. Tumors with nuclear ATRX loss and lack of H09 
binding to be sequenced for rare IDH mutations and H3F3A mutations: IDH mutations render these 
tumors astrocytoma, H3F3A mutations place into the GBM-H3 group. IDHmut tumors with nuclear 
ATRX expression require testing for the complete loss of 1p/19q. All tumors with 1p/19q co-deletion 
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represent oligodendrogliomas. This will also identify those IDHmut astrocytomas lacking both ATRX 
mutations and 1p/19q co-deletions. Further, all tumors proven IDHwt need not be tested for 1p/19q co-
deletion, as the latter alteration in practice always is associated with IDH mutations [11,19,29]. IDHwt 
tumors most likely represent GBM or misinterpreted other low grade glial or glioneuronal lesions. If 
diagnostically necessary, the analysis of TERT promoter mutations is helpful in distinguishing between 
these groups with TERT mutations exclusively present in the GBM group. The MID-HGG group 
currently cannot be distinguished without methylation profiling. A flow diagram of a possible approach 
is provided in fig.6. 
 
Conclusions 
Our data demonstrate that approximately 80% of IDHwt astrocytomas in fact represent 
underdiagnosed GBM or GBM-H3 and a smaller fraction represents misclassified lower grade tumors 
such as pilocytic astrocytomas, pleomorphic astrocytomas, DNTs or gangliogliomas. A further 8% of 
the IDHwt astrocytomas emerge as a new midline high grade glioma subset. 
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Table 1: Overview of 160 IDHwt astrocytomas divided into four distinct molecular groups  
 
 
     
Designation GBM GBM-H3 MID-HGG others 
n / (%) 124 (78%) 15 (9%) 13 (9%) 8 (7%) 
Methylation profile GBM (121) H3 distinct variant 
H3F3A-mutant 0 15 0 0 
TERT-mutant 84/108 
(78%) 
0 0 0 
ATRX-loss (IHC) 2/82 (2%) 8/11 (73%) 2/10 (20%) 0/6 (0%) 
7p gain/10q loss 83/124 
(67%) 
0 0  0 
EGFR amp 54/124 
(44%) 
0 0 0 
10q-/13q-/14q- 21/124 
(17%) 
1 (7%) 0 0 
OS median (months) 19.4 16.9 54.7 Not reached 
AA III n = 120 96 (80%) 12 (10%) 10 (8%) 1 (1%) 
A II n = 40 28 (70%) 3 (7%) 4 (10%) 7 (17%) 
Age median  54 51,5 54 49 
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Supplementary Table 1: Molecular alterations in the reference cohorts of IDHwt 
glioblastomas and IDHmut astrocytomas 
 
 
Molecular alteration AIII-IDH-mut GBM GBM-H3-
G34 
GBM-H3-K27 
pTERT 1/117 (1%) 80/93 (86%) 0/8 (0%) 0/7 (0%) 
7q gain / 10q het-del 0/132 (0%) 70/100 (70%) 2/10 (20%) 0/11 (0%) 
10q-/13q-/14q-  0/132 (0%) 20/100 (20%) 0/10 (0%) 0/11 (0%) 
EGFR amplifcation 1/132 (1%) 37/100 (37%) 1/10 (10%) 0/11 (0%) 
pTERT or 7p gain / 10q het-del  
or EGFR amp. 
2/132 (2%) 94/100 (94%) 2/10 (20%) 0/11 (0%) 
3q complex 3/132 (2%) 4/100 (4%) 1/10 (10%) 3/11 (27%) 
3q het-del  15/132 (11%) 10/100 (10%) 6/10 (60%) 0/11 (0%) 
MDM2 gain or amp 2/132 (2%) 9/100 (9%) 0/10 (0%) 6/11 (55%) 
17q gain  8/132 (6%) 5/100 (5%) 4/10 (40%) 3/11 (27%) 
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Supplementary Table 2: Molecular alterations in 160 patients with IDHwt astrocytoma 
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Figure legends 
 
Figure 1  
From top to bottom: a, typical copy number profile of GBM with gain of 7, loss of 10, CDKN2A 
deletion and EGFR amplification; b, CNP of GBM-H3-K27 with co-gain of MDM2/CDK4 and 
17q gain; c, CNP of a MID-HGG with a deletion on 3q and a 17q gain; d, typical profile of 
ganglioglioma with several whole chromosomal gains 
 
Figure 2 
Molecular profiling of non-CIMP IDH-wt astrocytomas and GBM and GBM-H3 reference 
cases. The dendrogram depicts the results of unsupervised hierarchical clustering of 
methylation levels of the top 18856 most variant probes (SD >0.20). The row “Tumor series” 
indicates study cases in red and reference cases in white. Diagnoses of reference cases 
were set prior to analysis and remained unchanged. Integrated diagnosis of study cases are 
indicated by different colors: GBM ~ glioblastoma (grey); GBM-H3-G34 ~ glioblastoma 
H3F3A-G34 mutated (green); GBM-H3-K27 ~ glioblastoma H3F3A-K27 mutated (yellow); 
MID-HGG ~ midline high grade glioma (light yellow); other (blue). For each sample 
associated results of TERT and H3F3A hotspot sequencing, ATRX-immunohistochemistry 
and selected chromosomal copy number variants are indicated: black indicated presence of 
the alteration, white indicates absence of the alteration, grey indicates unknown status. 
 
Figure 3 
Survival of patients: a, overview over survival of the four IDHwt groups compared with AIII-
IDHmut; b, survival of patients with integrated diagnoses of GBM (left) or GBM-H2F3A-K27-
mut (right) compared with patients diagnosed with IDHmut anaplastic astrocytoma; c, 
survival of patients of the MID-HGG group compared with GBM and GBM-H3-K27 (left) and 
AIII-IDHmut (right). 
 
Figure 4 
Changes from initial WHO to integrated diagnosis in 160 patients with IDHwt astrocytoma. 
Width of bars indicates relative proportions of the intital tumor groups. A II ~ diffuse 
astrocytoma WHO grade II; AA III ~ anaplastic astrocytoma WHO grade III; GBM ~ 
glioblastoma; GBM-H3 ~ glioblastoma H3F3A mutated; MID-HGG ~ midline high grade 
glioma 
 
Figure 5 
Different sets of tumors are included in the classification categories of astrocytoma NOS, 
IDHmut, IDHwt, and IDH1-R132H-IHC-negative. From left to right: Astrocytoma NOS 
includes different tumors with the histopathological features of astrocytomas (left). 
Astrocytoma IDHmut constitutes a homogenous group (middle left), astrocytoma IDHwt 
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(middle right) is a mixed bag with different tumors excluding astrocytoma IDHmut and 
astrocytoma IDH1-R132H-IHC-negative (right panel) is similar but contains those 
astrocytomas and oligodendrogliomas with rare IDH1 and IDH2 mutations. Size of boxes 
approximates the incidence in % and varies between institutions. PA = pilocytic astrocytoma, 
DNT = dysembryoplastic neuroepithelial tumor, GG = ganglioglioma, PXA = pleomorphic 
xanthoastrocytoma, O = oligodendroglioma 
 
Figure 6 
Diagnostic approach to tumors with diffuse astrocytic morphology starting with IDH1-R132H 
and ATRX immunohistochemistry. Following this diagnostic algorithm, an integrated 
diagnosis can be obtained with reduced involvement of molecular analyses. The MID-HGG 
group currently cannot be distinguished without methylation profiling. While the assessment 
of TERT promoter mutations is not required for distinguishing between distinct groups of 
malignant glioma (GBM, GBM-H3, MID-HGG), it may be helpful in separating IDHwt GBM 
from other IDHwt lower grade tumors. 
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